QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)

Eli Lilly and - LLY Stock Forecast, Price & News

$339.08
+8.38 (+2.53%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$329.37
$342.33
50-Day Range
$330.70
$374.76
52-Week Range
$231.87
$384.44
Volume
5.67 million shs
Average Volume
3.15 million shs
Market Capitalization
$322.19 billion
P/E Ratio
50.91
Dividend Yield
1.14%
Price Target
$384.89

Eli Lilly and MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.85 Rating Score
Upside/​Downside
13.3% Upside
$384.11 Price Target
Short Interest
Healthy
0.56% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.25
Upright™ Environmental Score
News Sentiment
0.45mentions of Eli Lilly and in the last 14 days
Based on 50 Articles This Week
Insider Trading
Acquiring Shares
$374.91 M Bought Last Quarter
Proj. Earnings Growth
6.88%
From $7.70 to $8.23 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.27 out of 5 stars

Medical Sector

5th out of 1,029 stocks

Pharmaceutical Preparations Industry

3rd out of 501 stocks

LLY stock logo

About Eli Lilly and (NYSE:LLY) Stock

Eli Lilly and Company is a US-based multinational pharmaceutical company. It is the 12th largest pharmaceutical company by revenue and has offices in 16 countries. Its medicines are sold in at least 125 countries including its 8 blockbuster drugs. The company is a member of the S&P 500 and S&P 100 indices, it brought in roughly $5.5 billion in revenue for 2021 and employs more than 35,000 people across its network of research and production facilities.

Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly. The colonel, a veteran of the Civil War, had recently dissolved an unsatisfactory partnership and set on his own to produce and develop medicinal chemicals. Colonel Lilly remained as president until his death in 1898. His charge to his family, company and coworkers was to “take what you find here and make it better and better”. The company is well-known for many drugs, including the first mass-marketing of quinine to treat malaria.

The company brought in $4,470 in its first year and saw that figure grow 10X over the next 3. Among the many innovations during this time period is the addition of gelation coatings for pills which helped set the company up for rapid expansion. The company was incorporated in 1881 as Eli Lilly and Company issuing stock to family and friends. The 1900s brought about more change for the company, change in the form of expansion which included international markets.

Advancements during the war years included increases in efficiency due to increased automation and the development of precision technologies. Among the technologies was pill manufacturing which included injecting medicines directly into a gelation capsule. This method allowed for more exact dosing, setting the standard for modern production. The company produced capsules for itself and sold excess capacity to competitors. Other major advancements include fruit flavorings in medicine, straight-line manufacturing and a method of blueprinting manufacturing tickets to prevent errors.

The modern period saw the company grow and discover new, world-class pharmaceuticals. Today, the company is engaged in the discovery, development and marketing of human pharmaceuticals. It offers a wide range of treatments, including Prozac but is perhaps most noteworthy for its work with insulin. The company is the first to mass produce insulin and has made numerous advances in treating diabetes in the time since. While other drugs are more widely known, its diabetic drugs Basaglar, Jardience, Trulicity, Humalog and Humulin are its top-sellers and contribute the bulk of revenue and cash flow.

Along with Diabetic research, the company also focuses on Alzheimer's, Oncology, Immunology, Obesity and Pain care. At the end of 2022, the company pipeline had 23 compounds in Phase 3 clinical trials and 1 in review. There were another 18 in Phase 2 trials and more than 2 dozen in Phase 1 trials. The average cost to discover a new drug was running at $2.6 billion with a 10-year discovery-to-patient timeline.

Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and and its competitors with MarketBeat's FREE daily newsletter.

LLY Stock News Headlines

Cassava Sciences Stock Undervalued with Its $124 Price Target? (LLY)
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a
Lilly shares slip as FDA seeks more Alzheimer's drug data
Eli Lilly shares slipped Friday morning after regulators said they need to see more data on the company’s application for a quick approval of its potential Alzheimer’s disease treatment
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
AbbVie Q4 Preview: What's in Store?
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Why Eli Lilly Stock Is Under Pressure Today
Lilly Lifts FY23 Earnings View Above Market On Updated Tax Rate - Update
Eli Lilly And Co. Reveals Rise In Q4 Bottom Line
Eli Lilly CEO weighs in on Q4 revenue miss
Eli Lilly raises 2023 profit forecast
Eli Lilly’s stock falls after Q4 revenue miss
See More Headlines
Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and and its competitors with MarketBeat's FREE daily newsletter.

LLY Company Calendar

Ex-Dividend for 12/9 Dividend
11/14/2022
Dividend Payable
12/09/2022
Last Earnings
2/02/2023
Today
2/03/2023
Ex-Dividend for 3/10 Dividend
2/14/2023
Dividend Payable
3/10/2023
Next Earnings (Estimated)
4/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
53245710
Employees
35,000
Year Founded
1876

Price Target and Rating

Average Stock Price Forecast
$384.11
High Stock Price Forecast
$455.00
Low Stock Price Forecast
$286.00
Forecasted Upside/Downside
+13.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
13 Analysts

Profitability

Net Income
$5.58 billion
Pretax Margin
22.40%

Debt

Sales & Book Value

Annual Sales
$28.32 billion
Cash Flow
$9.30 per share
Book Value
$9.57 per share

Miscellaneous

Free Float
949,038,000
Market Cap
$322.19 billion
Optionable
Optionable
Beta
0.35

Social Links


Key Executives

  • David A. RicksDavid A. Ricks
    Chairman, President & Chief Executive Officer
  • Anat AshkenaziAnat Ashkenazi
    Chief Financial Officer & Senior Vice President
  • Daniel M. SkovronskyDaniel M. Skovronsky
    Chief Scientific Officer & Senior Vice President
  • Diogo Rau
    Senior VP, Chief Information & Digital Officer
  • Alonzo WeemsAlonzo Weems
    Senior VP, Chief Ethics & Compliance Officer













LLY Stock - Frequently Asked Questions

Should I buy or sell Eli Lilly and stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LLY shares.
View LLY analyst ratings
or view top-rated stocks.

What is Eli Lilly and's stock price forecast for 2023?

13 analysts have issued 12 month price targets for Eli Lilly and's shares. Their LLY share price forecasts range from $286.00 to $455.00. On average, they anticipate the company's stock price to reach $384.11 in the next twelve months. This suggests a possible upside of 14.1% from the stock's current price.
View analysts price targets for LLY
or view top-rated stocks among Wall Street analysts.

How have LLY shares performed in 2023?

Eli Lilly and's stock was trading at $365.84 on January 1st, 2023. Since then, LLY stock has decreased by 8.0% and is now trading at $336.57.
View the best growth stocks for 2023 here
.

Are investors shorting Eli Lilly and?

Eli Lilly and saw a decrease in short interest in January. As of January 15th, there was short interest totaling 4,930,000 shares, a decrease of 12.3% from the December 31st total of 5,620,000 shares. Based on an average daily volume of 2,840,000 shares, the days-to-cover ratio is presently 1.7 days. Approximately 0.6% of the company's shares are sold short.
View Eli Lilly and's Short Interest
.

When is Eli Lilly and's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our LLY earnings forecast
.

How were Eli Lilly and's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) announced its quarterly earnings data on Thursday, February, 2nd. The company reported $2.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.83 by $0.26. The company earned $7.30 billion during the quarter, compared to analyst estimates of $7.39 billion. Eli Lilly and had a net margin of 20.63% and a trailing twelve-month return on equity of 80.80%. The business's quarterly revenue was down 8.7% on a year-over-year basis. During the same period in the prior year, the business earned $2.49 EPS.
Read the conference call transcript
.

How often does Eli Lilly and pay dividends? What is the dividend yield for Eli Lilly and?

Eli Lilly and declared a quarterly dividend on Monday, December 12th. Investors of record on Wednesday, February 15th will be paid a dividend of $1.13 per share on Friday, March 10th. This represents a $4.52 dividend on an annualized basis and a yield of 1.34%. The ex-dividend date of this dividend is Tuesday, February 14th. This is an increase from the stock's previous quarterly dividend of $0.98.
Read our dividend analysis for LLY
.

Is Eli Lilly and a good dividend stock?

Eli Lilly and (NYSE:LLY) pays an annual dividend of $3.92 per share and currently has a dividend yield of 1.14%. The company has been increasing its dividend for 9 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 58.86%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LLY will have a dividend payout ratio of 47.63% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LLY.

How will Eli Lilly and's stock buyback program work?

Eli Lilly and declared that its board has approved a share buyback plan on Monday, May 3rd 2021, which allows the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 2.8% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's board believes its stock is undervalued.

What guidance has Eli Lilly and issued on next quarter's earnings?

Eli Lilly and issued an update on its FY23 earnings guidance on Thursday, February, 2nd. The company provided earnings per share (EPS) guidance of $8.35-$8.55 for the period, compared to the consensus estimate of $8.31. The company issued revenue guidance of $30.3-$30.8 billion, compared to the consensus revenue estimate of $30.57 billion.

What is David A. Ricks' approval rating as Eli Lilly and's CEO?

399 employees have rated Eli Lilly and Chief Executive Officer David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among the company's employees.

What other stocks do shareholders of Eli Lilly and own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

What is Eli Lilly and's stock symbol?

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Who are Eli Lilly and's major shareholders?

Eli Lilly and's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Lilly Endowment Inc. (10.83%), Sumitomo Mitsui Trust Holdings Inc. (0.26%), New York State Common Retirement Fund (0.16%), New York State Teachers Retirement System (0.10%), DekaBank Deutsche Girozentrale (0.08%) and Assenagon Asset Management S.A. (0.06%). Insiders that own company stock include Aarti S Shah, Acquisition Corp Kearny, Alfonso G Zulueta, Alonzo Weems, Donald A Zakrowski, Ilya Yuffa, Jackson P Tai, Lilly Endowment Inc, Marschall S Runge, Melissa S Barnes, Myles O'neill and Stephen F Fry.
View institutional ownership trends
.

How do I buy shares of Eli Lilly and?

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eli Lilly and's stock price today?

One share of LLY stock can currently be purchased for approximately $336.57.

How much money does Eli Lilly and make?

Eli Lilly and (NYSE:LLY) has a market capitalization of $319.80 billion and generates $28.32 billion in revenue each year. The company earns $5.58 billion in net income (profit) each year or $6.66 on an earnings per share basis.

How many employees does Eli Lilly and have?

The company employs 35,000 workers across the globe.

Does Eli Lilly and have any subsidiaries?
The following companies are subsidiares of Eli Lilly and: 1096401 B.C. Unlimited Liability Company, ARMO Biosciences Inc., Acanthas Pharma Inc., Advanced Cardiovascular Systems, Alnara Pharmaceuticals, Alnara Pharmaceuticals Inc., Andean Technical Operations Center, Applied Molecular Evolution Inc., AurKa Pharma Inc., Avid Radiopharmaceuticals, Avid Radiopharmaceuticals Inc., ChemGen, CoLucid Pharmaceuticals, CoLucid Pharmaceuticals Inc., Compania Farmaceutica Eli Lilly de Centro America S.A., Dermira, Dermira Canada, Dermira Inc., Devices for Vascular Intervention(DVI), Disarm Therapeutics, Disarm Therapeutics, Disarm Therapeutics Inc., Dista Ilac Ticaret Ltd. Sti., Dista S.A., Dista-Produtos Quimicos & Farmaceuticos LDA, ELCO Dominicana SRL, ELCO Insurance Company Limited, ELCO Management Inc., ELCO for Trade and Marketing S.A.E., ELGO Insurance Company Limited, Elanco Animal Health Ireland Limited, Elanco Switzerland Holding Sarl, Eli Lilly (Malaysia) Sdn. Bhd., Eli Lilly (Philippines) Incorporated, Eli Lilly (S.A.) (Proprietary) Limited, Eli Lilly (Singapore) Pte. Ltd., Eli Lilly (Suisse) S.A., Eli Lilly Asia Inc., Eli Lilly Asia Pacific SSC Sdn Bhd, Eli Lilly Australia Pty. Limited, Eli Lilly B-H d.o.o., Eli Lilly Benelux S.A., Eli Lilly Bienes y Servicios S de RL de CV, Eli Lilly CR s.r.o., Eli Lilly Canada Inc., Eli Lilly Cork Limited, Eli Lilly Danmark A/S, Eli Lilly Egypt for Trading, Eli Lilly European Clinical Trial Services SA, Eli Lilly Export S.A., Eli Lilly Finance S.A., Eli Lilly Ges.m.b.H., Eli Lilly Group Limited, Eli Lilly Holdings Ltd., Eli Lilly Hrvatska d.o.o., Eli Lilly Interamerica Inc., Eli Lilly Interamerica Inc. y Compania Limitada, Eli Lilly International Corporation, Eli Lilly Ireland Holdings Limited, Eli Lilly Israel Ltd., Eli Lilly Italia S.p.A., Eli Lilly Japan K.K., Eli Lilly Kinsale Limited, Eli Lilly Nederland B.V., Eli Lilly Nigeria Ltd., Eli Lilly Norge A.S., Eli Lilly Pakistan (Pvt.) Ltd., Eli Lilly Polska Sp.z.o.o. (Ltd.), Eli Lilly Regional Operations GmbH, Eli Lilly Romania SRL, Eli Lilly S.A., Eli Lilly Saudi Arabia Limited, Eli Lilly Services India Private Limited, Eli Lilly Slovakia s.r.o., Eli Lilly Sweden AB, Eli Lilly Vostok S.A. Geneva, Eli Lilly and Company, Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (N.Z.) Limited, Eli Lilly and Company (Taiwan) Inc., Eli Lilly and Company Limited, Eli Lilly do Brasil Limitada, Eli Lilly farmacevtska druzba d.o.o., Eli Lilly y Compania de Mexico S.A. de C.V., Eli Lilly y Compania de Venezuela S.A., Glycostasis Inc., Greenfield-Produtos Farmaceuticos Lda., Heart Rhythm Technologies Inc, Hybritech, Hypnion, ICOS Corporation, ICOS Corporation, ImClone GmbH, ImClone LLC, ImClone Systems Holdings Inc., ImClone Systems LLC, Imclone Systems, Irisfarma S.A., Ivy Animal Health, LDH I Corporation, Lilly (Shanghai) Management Co. Ltd., Lilly Asia Ventures Fund I L.P., Lilly Asia Ventures Fund II L.P., Lilly Asian Ventures Fund III L.P., Lilly Cayman Holdings, Lilly Centre for Clinical Pharmacology PTE. LTD., Lilly China Research and Development Co. Ltd, Lilly Deutschland GmbH, Lilly France S.A.S., Lilly Global Nederland Holdings B.V., Lilly Global Services Inc., Lilly Holding GmbH, Lilly Holdings B.V., Lilly Hungaria KFT, Lilly Japan Financing G.K., Lilly Korea Ltd., Lilly Nederland Finance B.V., Lilly Nederland Finance B.V. - GCC, Lilly Nederland Holding B.V., Lilly Pharma Ltd., Lilly Portugal - Produtos Farmaceuticos Lda., Lilly S.A., Lilly Suzhou Pharmaceutical Co. Ltd., Lilly Trading Co. LTD, Lilly USA LLC, Lilly Ventures Fund I LLC, Lilly del Caribe Inc., Lilly ilaç ticaret limited şirketi, Lohmann Animal Health, Loxo Oncology, Loxo Oncology Inc., Novartis Animal Health, OY Eli Lilly Finland AB, Origin Medsystems, PT. Eli Lilly Indonesia, Pacific Biotech, Petra Pharma Corporation, Pharmaserve-Lilly S.A.C.I., Pharmaserve-Lilly S.A.C.I., Physio-Control, Prevail Therapeutics Inc., Protomer Technologies, SGX Pharmaceuticals, SGX Pharmaceuticals Inc., Spaly Bioquimica S.A., UAB Eli Lilly Lietuva, Valquifarma S.A., and Vital Pharma Productos Farmaceuticos.
Read More
How can I contact Eli Lilly and?

Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The official website for the company is www.lilly.com. The company can be reached via phone at (317) 276-2000, via email at johnson_philip_l@lilly.com, or via fax at 317-276-4878.

This page (NYSE:LLY) was last updated on 2/3/2023 by MarketBeat.com Staff